Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) Research & Development (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Research & Development for 6 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 12.82% year-over-year to $4.5 million, compared with a TTM value of $20.3 million through Dec 2025, down 1.49%, and an annual FY2025 reading of $20.3 million, down 1.49% over the prior year.
  • Research & Development was $4.5 million for Q4 2025 at Treace Medical Concepts, down from $4.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $5.6 million in Q1 2025 and bottomed at $1.9 million in Q1 2021.
  • Average Research & Development over 5 years is $4.0 million, with a median of $4.0 million recorded in 2022.
  • The sharpest move saw Research & Development surged 146.64% in 2021, then dropped 12.82% in 2025.
  • Year by year, Research & Development stood at $3.4 million in 2021, then rose by 11.02% to $3.7 million in 2022, then increased by 10.75% to $4.2 million in 2023, then grew by 25.48% to $5.2 million in 2024, then dropped by 12.82% to $4.5 million in 2025.
  • Business Quant data shows Research & Development for TMCI at $4.5 million in Q4 2025, $4.7 million in Q3 2025, and $5.5 million in Q2 2025.